Systemic treatment of hepatocellular carcinoma: Past, present and future - Wikidata - wikimedia - TriplyDB

Systemic treatment of hepatocellular carcinoma: Past, present and future

Systemic treatment of hepatocellular carcinoma: Past, present and future

http://www.wikidata.org/entity/Q33854034

about

Flipping a citrate switch on liver cancer cells.Crocin induces autophagic apoptosis in hepatocellular carcinoma by inhibiting Akt/mTOR activity.Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.Single cell profiling reveals window for immunotherapy in liver cancers.miRNA122a regulation of gene therapy vectors targeting hepatocellular cancer stem cells.Synergistic and independent action of endogenous microRNAs 122a and 199a for post-transcriptional liver detargeting of gene vectors MicroRNA199a-Based Post-transcriptional Detargeting of Gene Vectors for Hepatocellular Carcinoma

P2860

Q41484693-D0D96985-75B7-4981-8908-940E9FB9910C Q52579377-B3BB2A49-7C8A-4964-9582-370749B5F1E3 Q55080589-F8DF3EA6-B340-4B33-8E0F-1DC0A618136D Q55259096-6E9E972E-7009-4CCE-8AD2-BB8949044286 Q55360763-A96A53B2-F4D7-471D-889F-32D029DDC6D5 Q57811391-E032DB38-AD5C-4704-8D10-7FD27CA147F6 Q58704496-995A33D9-EB02-405B-BB71-0A7A8BBEF367

P2860

Systemic treatment of hepatocellular carcinoma: Past, present and future

http://www.wikidata.org/entity/Q33854034

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Systemic treatment of hepatocellular carcinoma: Past, present and future

@ast

Systemic treatment of hepatocellular carcinoma: Past, present and future

@en

type

label

Systemic treatment of hepatocellular carcinoma: Past, present and future

@ast

Systemic treatment of hepatocellular carcinoma: Past, present and future

@en

prefLabel

Systemic treatment of hepatocellular carcinoma: Past, present and future

@ast

Systemic treatment of hepatocellular carcinoma: Past, present and future

@en

P1433

Q33854034-E72ADEAE-BDE0-42C2-89D7-F06507FACC5B

P1476

Q33854034-7E903349-5169-4752-B4E8-4C06137860D5

P2093

Q33854034-F2A0DCF4-6CDA-4688-804C-89FED0F327BB

P2860

Q33854034-01446E60-30BE-426F-B65D-C153A98E64AD

Q33854034-0175573F-8788-47F4-8D98-54BBCAF95606

Q33854034-049E3C49-CCA8-448A-B89B-7FCC099A998E

Q33854034-04C7809B-8D93-47DE-81B1-32198F4D1572

Q33854034-0A6982A4-B767-42DE-84D7-00AD7B39FD19

Q33854034-0C093261-21AD-4A2C-8330-432A67F2C261

Q33854034-0F87320F-22A3-4E9D-94E5-AE7087EF1368

Q33854034-14DB47EA-19C1-4929-AA59-57606F268961

Q33854034-280A4ADB-9231-4677-8D84-69AB2D71F6CB

Q33854034-2A6662A0-DEFA-4E92-86EF-34E582B0B13D

P304

Q33854034-07A61A11-521F-4801-BB6B-B1F57F942457

P31

Q33854034-5C252917-98CE-488A-ADC8-0DBCA95D6806

P356

Q33854034-94F4F0F0-A33E-4119-8A35-E4D63F19A3BA

P433

Q33854034-FABB230A-D6DF-45B4-AF1F-A74CDFF25844

P478

Q33854034-B3700686-4C07-4111-8096-65596180F10A

P577

Q33854034-1AA03731-00F8-44AF-80BA-D233C4068D9D

P698

Q33854034-49E64092-1748-41A8-8BF5-9CD6438076D7

P932

Q33854034-C9E4DA75-AAC0-4BA8-9D7D-0E4D9E26B575

P356

P1433

World journal of hepatology

P1476

Systemic treatment of hepatocellular carcinoma: Past, present and future

@en

P2093

Esther Una Cidon

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

Progress in systemic therapy of advanced hepatocellular carcinoma

CTLA-4 blockade in tumor models: an overview of preclinical and translational research

A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.

Hormonal therapy with megestrol in inoperable hepatocellular carcinoma characterized by variant oestrogen receptors

Megestrol treatment in patients with hepatocellular carcinoma

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Prognosis of hepatocellular carcinoma: the BCLC staging classification

Primary liver cancer: worldwide incidence and trends

P304

797-807

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4254/WJH.V9.I18.797

http://www.w3.org/2001/XMLSchema#string

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28706578

http://www.w3.org/2001/XMLSchema#string

P932

5491402

http://www.w3.org/2001/XMLSchema#string